X-linked adrenoleukodystrophy (X-ALD) ranks as the most common peroxisomal disorder that primarily affects the adrenal glands and the nervous system. It is estimated that the prevalence of X-linked adrenoleukodystrophy is between 1 in 14,000 and 1 in 17,000 male births. X-ALD is caused by the buildup of very long chain fatty acids (VLCFA) as a result of the failure of peroxisomal fatty acid beta-oxidation. Since this rare genetic disorder leads to progressive neurological decline and adrenal insufficiency, there is a growing demand for advanced treatment options that can address the unmet medical needs of the patient population.
Major companies involved in the X-linked adrenoleukodystrophy (X-ALD) pipeline drugs market include Minoryx Therapeutics, S.L. and Viking Therapeutics, Inc., among others.
Leading drugs currently under the pipeline include MIN-102 and PXL065, among others.
The presence of regulatory incentives for rare diseases and the rising advancements in research that facilitate the identification of new therapeutic targets is a significant trend in the drug pipeline for X-linked adrenoleukodystrophy.
The X-Linked Adrenoleukodystrophy (X-ALD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into X-linked adrenoleukodystrophy (X-ALD) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for X-linked adrenoleukodystrophy (X-ALD). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The X-linked adrenoleukodystrophy (X-ALD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from X-linked adrenoleukodystrophy (X-ALD).
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to X-linked adrenoleukodystrophy (X-ALD).
X-linked adrenoleukodystrophy (X-ALD), a rare progressive peroxisomal disorder, is characterized by the accumulation of very long chain fatty acids in the nervous system and adrenal cortex. The condition affects more males than females and is linked to the X chromosome. Behavioral and cognitive changes are the common symptoms of X-ALD. The treatment for this genetic disorder is focused on halting or slowing the progression of the disease and improving patient symptoms.
Corticosteroid replacement therapy is recommended for the treatment of adrenal insufficiency in X-ALD patients. To slow the progression of the disease in children, stem cell transplant is the only treatment available. Medications are often prescribed for managing symptoms such as muscle stiffness or seizures. The lack of effective treatments and the severe nature of the disease are encouraging significant investment and research to address the unmet medical needs of the affected patients.
This section of the report covers the analysis of X-Linked Adrenoleukodystrophy (X-ALD) drugs based on several segmentations including:
By Phase:
By Drug Class:
By Route of Administration:
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for X-linked adrenoleukodystrophy (X-ALD).
The drug molecule categories covered under X-linked adrenoleukodystrophy (X-ALD) pipeline analysis include oligonucleotide, peptide, and small molecule. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for X-linked adrenoleukodystrophy (X-ALD).
The EMR report for the X-linked adrenoleukodystrophy (X-ALD) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in X-linked adrenoleukodystrophy (X-ALD) clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Poxel SA, the objective of this open-label Phase 2a clinical trial is to evaluate the pharmacokinetics and pharmacodynamic parameters of PXL065, a novel drug candidate, after 12 weeks of treatment in around 12 male participants who are affected by adrenomyeloneuropathy, a type of x-linked adrenoleukodystrophy.
Minoryx Therapeutics, S.L. is conducting a Phase II multi-center clinical trial to investigate the effects of MIN-102, an orally bioavailable and selective PPAR gamma agonist, in an estimated 13 male pediatric patients suffering from cerebral X-linked adrenoleukodystrophy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The X-Linked Adrenoleukodystrophy (X-ALD) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for X-linked adrenoleukodystrophy (X-ALD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within X-linked adrenoleukodystrophy (X-ALD) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share